Yan Leyfman, MD, Hematology-Oncology Fellow at NewYork-Presbyterian Brooklyn Methodist Hospital, shared on X:
“CML has changed. Have our treatment algorithms kept up?
The era of simply choosing a TKI and monitoring response is behind us.
Today, treating chronic myeloid leukemia means navigating an increasingly complex set of decisions:
- Which TKI should you start – and for whom?
- When should an inadequate response trigger a switch?
- How should resistance mutations change treatment selection?
- Where do newer agents fit into sequencing?
- Who can safely pursue treatment-free remission – and when?
At this week’s MedNews Week Keynote Conference, we go directly into these questions with Dr. Jorge Cortes, one of the investigators who helped build the evidence base behind modern CML therapy.
The CML Evolution:
Mastering Modern Algorithms in Chronic Myeloid Leukemia
Dr. Cortes breaks down how CML management has evolved and, more importantly, how to translate that evolution into real-world treatment decisions at the bedside.
Now at the University of Alabama at Birmingham, Dr. Cortes has led 90+ Phase I–III clinical trials, authored 1,000+ scientific publications, abstracts, and academic contributions, and held major international leadership roles in CML—including leadership of the International Chronic Myeloid Leukemia Foundation.
This isn’t just a review of CML.
It is an opportunity to learn how one of the field’s most influential investigators thinks through the decisions that define modern CML care.
- September 16, 2026
- 12:30 PM ET
- MedNews Week Keynote Conference
Catch This Episode exclusively on OncoDaily TV.
From first-line therapy – resistance – sequencing – treatment-free remission.
If you treat leukemia-or are training to-this is one conversation worth hearing.”
You can also read: BCR::ABL1-Rearranged Chronic Myeloid Leukemia: Molecular Basis, TKI Resistance and Emerging Therapies
